Brain-activated therapy
for stroke recovery.
Non-invasive therapy for motor function
rehabilitation with IpsiHandTM
IpsiHandâ„¢ is an FDA-cleared non-invasive device for rehabilitation of upper extremity motor function after stroke.
What is IpsiHand?
The IpsiHand is the first FDA-cleared device leveraging brain-computer interface (BCI) technology to assist chronic stroke patients in rehabilitation.
The device utilizes the uninjured, or ipsilateral, side of the brain to improve arm and hand function.
Therapeutic device with
long-lasting results.
IpsiHand results are durable and retained. Six months after using IpsiHand, improvements in upper extremity function remained consistent.
This sets IpsiHand apart from other rehabilitation technologies, which typically show no carryover in function.
+10.2 AMAT
On the AMAT
(Arm Motor Ability Test).
Are your patients the right fit?
Many stroke recovery patients have the cognitive capabilities needed to make progress, but just don’t feel like their brain and body are connecting. IpsiHand is a great fit for motivated patients ready to take ownership in their recovery journey.
Here are three criteria to determine if a patient might be a good fit:
01.
They are struggling with a plateau in their recovery.
02.
They are ready to make advancements in regaining use of their upper extremity.
03.
They are looking to enhance their current therapy program.
Why IpsiHand?
Scientifically-backed and Clinically-tested
The EEG headset pulls cortical signals from hand regions in the primary cortex of the ipsilateral cerebral hemisphere, sending them to the computer processor to make the handpiece move in real time. With regular use following exercise prompts on their tablet, IpsiHand users show the presence of biomarkers in the brain that demonstrates motor remodeling.
Convenience and Ease of Access
Often, the intensity required for motor improvement isn’t achieved in outpatient therapy alone. That’s why IpsiHand is designed for independent use by patients at home. By improving patient access to home therapy, IpsiHand users can log more therapeutic program hours without direct supervision of an occupational or physical therapist.
By using the IpsiHand, patients can have improved access, reduced impacts from the social determinants of health, and avoid transportation-related restrictions. Ultimately, this therapy option can increase the potential for significant cost savings compared to other therapeutic neuro-technologies.
Headset
Decodes electrical signals from uninjured brain.
Handpiece
Specific signals are sent to Handpiece
Tablet
Visual imagery guidance on tablet.
Prescribing IpsiHand: The Process
01. Identifying Ideal Candidates
Patients are indicated to use IpsiHand if they are chronic stroke patients (≥ six months post-stroke), age 18 or older, and undergoing rehabilitation to facilitate muscle re-education and maintaining or increasing range of motion in the upper extremity.
02. Prescribing IpsiHand
Standard prescription and insurance forms are available in our clinical resource center for your convenience. These include all necessary and supplemental information for prescribing IpsiHand System to your patients.
03. What’s Next?
Upon receipt of a valid prescription and insurance approval for coverage, the Neurolutions clinical staff works with the patient to schedule an EEG Signal Test and evaluate the patient’s motor intent signals. This crucial step ensures the patient is a suitable candidate for the IpsiHand.
Clinically-backed Claims
2022 Brain Communications Publication
Theta–gamma coupling as a cortical biomarker of brain–computer interface.
2022 Brain-Computer Interfaces Publication
Motor Network Reorganization Induced in Chronic Stroke Patients with interface.
Sept 30, 2024 Publication
IpsiHand Brain–Computer Interface Therapy
Food & Drug Administration
IpsiHand is FDA Cleared
– via De Novo
First prescriptive
orders for private pay home patients received.
Neurolutions Awarded
California Life Science Medical Device of the year.
SBIR Awarded $2M
to Neurolutions.
First Clinical Trial Complete
Published on Cover of Stroke
Reclaim Independence
Approximately 300,000 Americans each year suffer from post-stroke hemiparesis.
Breakthrough Research
Newly published studies show motor recovery in chronic stroke patients.
FDA Granted
IpsiHand as a “Breakthrough Medical Technology“